Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 1.34 MB
Add to list
  1. Search results
  2. Metastases-directed stereotactic body...

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

Stephanie G C Kroeze, Matea Pavic, Karin Stellamans, Yolande Lievens (UGent) , Carlotta Becherini, Marta Scorsetti, Filippo Alongi, Umberto Ricardi, Barbara Alicja Jereczek-Fossa, Paulien Westhoff, et al.
(2023) LANCET ONCOLOGY. 24(3). p.e121-e132
Author
Organization
Abstract
Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted therapy or immunotherapy has become a frequently practised and guideline-supported treatment strategy. Despite the increasing use in routine clinical practice, there is little information on the safety of combining SBRT with modern targeted therapy or immunotherapy and a paucity of high-level evidence to guide clinical management. A systematic literature review was performed to identify the toxicity profiles of combined metastases-directed SBRT and targeted therapy or immunotherapy. These results served as the basis for an international Delphi consensus process among 28 interdisciplinary experts who are members of the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) OligoCare consortium. Consensus was sought about risk mitigation strategies of metastases-directed SBRT combined with targeted therapy or immunotherapy; a potential need for and length of interruption to targeted therapy or immunotherapy around SBRT delivery; and potential adaptations of radiation dose and fractionation. Results of this systematic review and consensus process compile the best available evidence for safe combination of metastases-directed SBRT and targeted therapy or immunotherapy for patients with metastatic or oligometastatic cancer and aim to guide today's clinical practice and the design of future clinical trials.
Keywords
Oncology

Downloads

  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.34 MB

Citation

Please use this url to cite or link to this publication:

MLA
Kroeze, Stephanie G. C., et al. “Metastases-Directed Stereotactic Body Radiotherapy in Combination with Targeted Therapy or Immunotherapy : Systematic Review and Consensus Recommendations by the EORTC–ESTRO OligoCare Consortium.” LANCET ONCOLOGY, vol. 24, no. 3, Elsevier BV, 2023, pp. e121–32, doi:10.1016/s1470-2045(22)00752-5.
APA
Kroeze, S. G. C., Pavic, M., Stellamans, K., Lievens, Y., Becherini, C., Scorsetti, M., … Guckenberger, M. (2023). Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium. LANCET ONCOLOGY, 24(3), e121–e132. https://doi.org/10.1016/s1470-2045(22)00752-5
Chicago author-date
Kroeze, Stephanie G C, Matea Pavic, Karin Stellamans, Yolande Lievens, Carlotta Becherini, Marta Scorsetti, Filippo Alongi, et al. 2023. “Metastases-Directed Stereotactic Body Radiotherapy in Combination with Targeted Therapy or Immunotherapy : Systematic Review and Consensus Recommendations by the EORTC–ESTRO OligoCare Consortium.” LANCET ONCOLOGY 24 (3): e121–32. https://doi.org/10.1016/s1470-2045(22)00752-5.
Chicago author-date (all authors)
Kroeze, Stephanie G C, Matea Pavic, Karin Stellamans, Yolande Lievens, Carlotta Becherini, Marta Scorsetti, Filippo Alongi, Umberto Ricardi, Barbara Alicja Jereczek-Fossa, Paulien Westhoff, Jasna But-Hadzic, Joachim Widder, Xavier Geets, Samuel Bral, Maarten Lambrecht, Charlotte Billiet, Igor Sirak, Sara Ramella, Ivaldi Giovanni Battista, Sergi Benavente, Almudena Zapatero, Fabiola Romero, Thomas Zilli, Kaouthar Khanfir, Hossein Hemmatazad, Berardino de Bari, Desiree N Klass, Shaukat Adnan, Heike Peulen, Juan Salinas Ramos, Michiel Strijbos, Sanjay Popat, Piet Ost, and Matthias Guckenberger. 2023. “Metastases-Directed Stereotactic Body Radiotherapy in Combination with Targeted Therapy or Immunotherapy : Systematic Review and Consensus Recommendations by the EORTC–ESTRO OligoCare Consortium.” LANCET ONCOLOGY 24 (3): e121–e132. doi:10.1016/s1470-2045(22)00752-5.
Vancouver
1.
Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium. LANCET ONCOLOGY. 2023;24(3):e121–32.
IEEE
[1]
S. G. C. Kroeze et al., “Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium,” LANCET ONCOLOGY, vol. 24, no. 3, pp. e121–e132, 2023.
@article{01H4RADJQ1HJRWNCQSGX61Z9WH,
  abstract     = {{Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted therapy or immunotherapy has become a frequently practised and guideline-supported treatment strategy. Despite the increasing use in routine clinical practice, there is little information on the safety of combining SBRT with modern targeted therapy or immunotherapy and a paucity of high-level evidence to guide clinical management. A systematic literature review was performed to identify the toxicity profiles of combined metastases-directed SBRT and targeted therapy or immunotherapy. These results served as the basis for an international Delphi consensus process among 28 interdisciplinary experts who are members of the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) OligoCare consortium. Consensus was sought about risk mitigation strategies of metastases-directed SBRT combined with targeted therapy or immunotherapy; a potential need for and length of interruption to targeted therapy or immunotherapy around SBRT delivery; and potential adaptations of radiation dose and fractionation. Results of this systematic review and consensus process compile the best available evidence for safe combination of metastases-directed SBRT and targeted therapy or immunotherapy for patients with metastatic or oligometastatic cancer and aim to guide today's clinical practice and the design of future clinical trials.}},
  author       = {{Kroeze, Stephanie G C and Pavic, Matea and Stellamans, Karin and Lievens, Yolande and Becherini, Carlotta and Scorsetti, Marta and Alongi, Filippo and Ricardi, Umberto and Jereczek-Fossa, Barbara Alicja and Westhoff, Paulien and But-Hadzic, Jasna and Widder, Joachim and Geets, Xavier and Bral, Samuel and Lambrecht, Maarten and Billiet, Charlotte and Sirak, Igor and Ramella, Sara and Giovanni Battista, Ivaldi and Benavente, Sergi and Zapatero, Almudena and Romero, Fabiola and Zilli, Thomas and Khanfir, Kaouthar and Hemmatazad, Hossein and de Bari, Berardino and Klass, Desiree N and Adnan, Shaukat and Peulen, Heike and Salinas Ramos, Juan and Strijbos, Michiel and Popat, Sanjay and Ost, Piet and Guckenberger, Matthias}},
  issn         = {{1470-2045}},
  journal      = {{LANCET ONCOLOGY}},
  keywords     = {{Oncology}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{e121--e132}},
  publisher    = {{Elsevier BV}},
  title        = {{Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium}},
  url          = {{http://doi.org/10.1016/s1470-2045(22)00752-5}},
  volume       = {{24}},
  year         = {{2023}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: